CLIE SCIE After several questions have been received, the Board of
"After the Company's rights issue has been closed and the outcome compiled, we want to start by thanking our shareholders for their continued trust. Our assessment is that it is still difficult for R&D companies to raise capital and based on this we are satisfied with the outcome. We made a strategic decision to keep the discount for the issue offer down and minimize the issue costs in the rights issue with respect to our existing shareholders. We have now received enough capital to carry on Cline's operations in an efficient manner. Our ambition is of course to manage the capital we have raised through the rights issue and maximize the value for our shareholders.
The board has already discussed various action plans based on potential outcomes in the rights issue before the rights issue. We are therefore ready to act, which means that we will prioritize strategic activities in the StemCART and CellRACE projects. We will update the market on an ongoing basis regarding these activities. Furthermore, we continuously review the capital requirement, financing options, and the Company's strategy to be able to reach important milestones going forward.
Finally, we would like to point out that despite a difficult financing climate, Cline can continue its operations in the cost-effective way we have done since the beginning in 2012. We thank you shareholders again who make this possible for us!"
For more information, please contact:
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
About
Argongatan 2C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline's unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
https://news.cision.com/cline/r/the-board-of-directors-comment-on-the-outcome-of-the-rights-issue,c3676393
https://mb.cision.com/Main/12114/3676393/1710897.pdf
(c) 2022 Cision. All rights reserved., source
